Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. - Wikidata - awgldk - TriplyDB

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

http://www.wikidata.org/entity/Q37850800

about

Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization.The Best Anticoagulation Strategy for Cirrhotic Patients who Underwent Splenectomy: A Network Meta-Analysis.

P2860

Q36093372-33DF561C-64E8-4133-97C0-E50396EB1E73 Q38693795-6D7B6FA3-C959-4624-AF88-B11E02D2F69D

P2860

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

http://www.wikidata.org/entity/Q37850800

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

@en

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

@nl

type

label

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

@en

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

@nl

prefLabel

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

@en

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

@nl

P1433

Q37850800-E6AD1252-EAF2-4141-93AE-9BB10985A5C7

P1476

Q37850800-0BD153EB-C23C-4FB6-92AF-B9072F43AD1E

P2093

Q37850800-CEDDC0B8-D728-492E-AC95-6662560FF2CD

P2860

Q37850800-0224A22C-917B-427F-A56E-E01A2FFCF9A5

Q37850800-0508DA8C-EE68-4DA5-BDEC-0DF098C9E5C8

Q37850800-0557507A-AA5E-4A12-A1D0-83A6814687DD

Q37850800-0ECB6DA2-FF71-400F-A8A4-BCD8D1AA0005

Q37850800-217BCB1C-E82C-40BB-9507-DE36CCCC7CE8

Q37850800-2374550E-2E5A-43DE-87CE-15937F03285C

Q37850800-2CDA4E7B-9F96-4E7A-9C8A-50BDEC01EB4D

Q37850800-315C549F-061B-4FC2-8AC3-F34B75EF11E8

Q37850800-31BFC5FD-EFFC-4504-A9F9-ED5AFF9E1223

Q37850800-39B23166-B153-4D51-B4F6-53F24D993076

P304

Q37850800-E78B5BC5-22AB-4BA2-83D2-E1B5EF3DBD3B

P31

Q37850800-306552EF-F9BB-4503-AC9C-188FC5AAA6BA

P356

Q37850800-8644092C-5B75-4DC8-8777-DFBE51BD93A0

P407

Q37850800-E19BF615-84E7-45AD-A954-467231FC790D

P433

Q37850800-670ACA6F-D17D-41E0-8FC2-2E36ECB0D986

P478

Q37850800-816972C7-E34E-4D7F-BF6C-42D0AC064A77

P50

Q37850800-CC03ECFF-F543-4CB7-A63D-BF14A5809B27

P577

Q37850800-37B2A6F9-C415-43A6-A096-BF7F75072937

P698

Q37850800-0EE31892-0D9D-4FE4-BD90-0ECF19E06617

P921

Q37850800-08B58CBE-968D-4F0B-A5FB-8AF1A18D5332

P356

13543784.2011.562190

P1433

Expert Opinion on Investigational Drugs

P1476

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes

@en

P2093

Erica Romualdi

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

Oral rivaroxaban for symptomatic venous thromboembolism

Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.

P304

495-505

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2011.562190

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21385107

http://www.w3.org/2001/XMLSchema#string

P921